Skip to main content

All News

ORNL's Communications team works with news media seeking information about the laboratory. Media may use the resources listed below or send questions to news@ornl.gov.

1 - 10 of 23 Results

Transformational Challenge Reactor Demonstration items

Researchers at the Department of Energy’s Oak Ridge National Laboratory are refining their design of a 3D-printed nuclear reactor core, scaling up the additive manufacturing process necessary to build it, and developing methods

Data scientists at Oak Ridge National Laboratory have completed a study of long-term trends in the relationship between the timing of tree leafing and rising temperatures in the United States. The information is being incorporated into DOE’s Energy Exascale Earth System Model. Photo Credit: Oak Ridge National Laboratory, U.S. Dept. of Energy

A team of scientists led by Oak Ridge National Laboratory found that while all regions of the country can expect an earlier start to the growing season as temperatures rise, the trend is likely to become more variable year-over-year in hotter regions.

A pilot reactor, developed by Vertimass and located at TechnipFMC, can scale up the process that converts ethanol into fuels suitable for aviation, shipping and other heavy-duty applications. Credit: TechnipFMC.

A technology developed at the ORNL and scaled up by Vertimass LLC to convert ethanol into fuels suitable for aviation, shipping and other heavy-duty applications can be price-competitive with conventional fuels

CellSight allows for rapid mass spectrometry of individual cells. Credit: John Cahill, Oak Ridge National Laboratory/U.S. Dept of Energy

Researchers at the Department of Energy’s Oak Ridge National Laboratory have received five 2019 R&D 100 Awards, increasing the lab’s total to 221 since the award’s inception in 1963.

Cropped INFUSE logo

The U.S. Department of Energy announced funding for 12 projects with private industry to enable collaboration with DOE national laboratories on overcoming challenges in fusion energy development.

Summit supercomputer

Processes like manufacturing aircraft parts, analyzing data from doctors’ notes and identifying national security threats may seem unrelated, but at the U.S. Department of Energy’s Oak Ridge National Laboratory, artificial intelligence is improving all of these tasks.

Electro-Active Tech license signing ceremony

Electro-Active Technologies, Inc., of Knoxville, Tenn., has exclusively licensed two biorefinery technologies invented and patented by the startup’s co-founders while working at the Department of Energy’s Oak Ridge National Laboratory. The technologies work as a system that converts organic waste into renewable hydrogen gas for use as a biofuel.

early prototype of the optical array developed by Oak Ridge National Laboratory.

IDEMIA Identity & Security USA has licensed an advanced optical array developed at Oak Ridge National Laboratory. The portable technology can be used to help identify individuals in challenging outdoor conditions.

Laccaria bicolor is fruiting aboveground and colonizing the Populus deltoides plant root system belowground in a greenhouse setting.

A team of scientists led by Oak Ridge National Laboratory have discovered the specific gene that controls an important symbiotic relationship between plants and soil fungi, and successfully facilitated the symbiosis in a plant that typically resists it.

(From left) ORNL Associate Laboratory Director for Computing and Computational Sciences Jeff Nichols; ORNL Health Data Sciences Institute Director Gina Tourassi; DOE Deputy Under Secretary for Science Thomas Cubbage; ORNL Task Lead for Biostatistics Blair Christian; and ORNL Research Scientist Ioana Danciu were invited to the White House to showcase an ORNL-developed digital tool aimed at better matching cancer patients with clinical trials.

OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.